Vés al contingut

Leading scientific associations and innovative companies demand to place R&D at the heart of our country’s strategy

Images

Contact

Imatge
Section Head of Communication & Outreach
Tel.+34 93 40 37255

The announcement is made in light of the recent approval of the preliminary draft of the Spanish government’s budget which announces an investment of more than five billion euros in science.

The signatories demand a national pact that includes long-term strategies aimed at promoting frontier science and business innovation.

The document aims to add and provide strategic solutions to the recent Pact for Science and Innovation that the Government has just announced.

SOMMa, ASEICA and AseBio, entities that together account for almost ten thousand researchers across the public and private sector, dozens of research centres and nearly 300 leading Spanish companies in the biotechnology sector, join their voices to urge the political class to transform the country. More than 40 organisations supporting stronger support for science and innovation have signed a document that calls for Spain to reach and exceed 2.5% investment in R&D by 2027 and radically change its current economic model.

The signatories consider this is a crucial moment of putting R&D at the centre of Spain’s future strategy for a sustainable and resilient recovery. It is a unique window of opportunity presented by yesterday’s preliminary draft of the state’s new general budget, the European Reconstruction Plan, the "Green Deal" and the missions of the new Horizon Europe Framework Program of the European Union.

Furthermore, the public has been able to grasp the need to have a solid research capacity for the challenges we are currently facing. Despite this, Spain invests just 1.24% of its GDP in R&D, a figure much lower than the EU average (2.12%), and far from countries such as Germany, Denmark or Austria (around 3%).

The call for action proposes a broad range of administrative and legal recommendations, as well as the implementation of strategic actions so that science and innovation act as the engines for the recovery of the country. The transformation of the economic model would counterbalance the dependence of sectors heavily affected by the current pandemic, giving Spain new opportunities and a stronger position for the future. Crystallizing the great Spanish potential in R&D would lay the foundations for a solid recovery through a sustainable, competitive economic model based on providing high added value.

“The current context has abruptly exposed the shortcomings of our economic model. Spain is thought to be one of the advanced economies most affected by the pandemic, making it essential to change the foundations of our economic model before we can regrow. This is a turning point which we cannot back away from, as it is only through a new economic model that we can ensure the future of Spain. Taking urgent action through the state’s general budget is just the starting point. A state pact for R&D is necessary now more than ever." Luis Serrano, president of SOMMa and director of the Centre for Genomic Regulation.

“Covid-19 has revealed what we have been warning for a long time: the urgent need to invest in science and innovation to ensure the health of our citizens and to develop an economy based on knowledge, not entertainment. We must take the bull by the horns: we need stable long-term plans and short-term solutions to meet these challenges. Let's say it once again: research is not a luxury, it is the only way we have to ensure the health and quality of life of our fellow citizens. And this does not depend on ideologies, it is a project that cuts across all divides”. Xosé Bustelo, President of ASEICA.

“This appeal to our political representatives, to the administration and to society itself, is nothing but a joint demand for a long-term strategy that promotes science and innovation in our country and places them at the heart of its strategy. Innovative companies and entities are committed to this effort if we have an adequate and stable framework that allows us to work collaboratively with the rest of the agents of the R & D & I ecosystem and thus contribute to the transformation of our production model." Ion Arocena, CEO of AseBio.

The appeal led by SOMMa, ASEICA and AseBio centres around three groups of measures, the first of which focuses on the strengthening of basic and translational frontier science. The signatories demand a simplification of expense management and associated bureaucracy, an increase and optimization of investment, new talent recruitment programs, and mechanisms that favour the stability of research projects promoted by public organizations.

The second tier of recommendations propose measures that strengthen innovation and promote the transition to a sustainable economy with high added value. It is proposed to promote public-private cooperation and innovative business fabric, as well as the creation of a patronage-fundraising law. It also calls for a need to undertake a profound reform of the aid model for business R&D and a legal framework that minimizes uncertainties and provides stability and security to the R&D system.

Finally, the third tier of recommendations call for new mechanisms to increase synergies between the academic and business sectors. Key to this will be the development of a long-term national strategy that includes the autonomous communities, increasing the capacity to transfer the knowledge of universities and research institutes into innovative solutions and the creation of new technology-based companies. Finally, the signatories appeal to cultivate the value of science as a reference for citizenship, the business community and political action.

 

You can find the full document with the list of signatories here (in Spanish).

IRB Barcelona

L’Institut de Recerca Biomèdica (IRB Barcelona) treballa per aconseguir una vida lliure de malalties. Desenvolupa una recerca multidisciplinària d’excel·lència per curar el càncer i altres malalties vinculades a l'envelliment. Treballa establint col·laboracions amb la indústria farmacèutica i els principals hospitals per fer arribar els resultats de la recerca a la societat a través de la transferència de tecnologia, i du a terme diferents iniciatives de divulgació científica per mantenir un diàleg obert amb la ciutadania. L’IRB Barcelona és un centre internacional que acull al voltant de 400 investigadors de més de 30 nacionalitats. Reconegut com a Centre d'Excel·lència Severo Ochoa des de 2011, és un centre CERCA i membre del Barcelona Institute of Science and Technology (BIST).